Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ohtsu, Atsushi | - |
dc.contributor.author | Ajani, Jaffer A. | - |
dc.contributor.author | Bai, Yu-Xian | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Chung, Hyun-Cheol | - |
dc.contributor.author | Pan, Hong-Ming | - |
dc.contributor.author | Sahmoud, Tarek | - |
dc.contributor.author | Shen, Lin | - |
dc.contributor.author | Yeh, Kun-Huei | - |
dc.contributor.author | Chin, Keisho | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Ferry, David | - |
dc.contributor.author | Tebbutt, Niall C. | - |
dc.contributor.author | Al-Batran, Salah-Eddin | - |
dc.contributor.author | Smith, Heind | - |
dc.contributor.author | Costantini, Chiara | - |
dc.contributor.author | Rizvi, Syed | - |
dc.contributor.author | Lebwohl, David | - |
dc.contributor.author | Van Cutsem, Eric | - |
dc.date.accessioned | 2021-09-05T19:23:24Z | - |
dc.date.available | 2021-09-05T19:23:24Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2013-11-01 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/101639 | - |
dc.description.abstract | Purpose The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared everolimus efficacy and safety with that of best supportive care (BSC) in previously treated advanced gastric cancer. Patients and Methods Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were randomly assigned to everolimus 10 mg/d (assignment schedule: 2: 1) or matching placebo, both given with BSC. Randomization was stratified by previous chemotherapy lines (one v two) and region (Asia v rest of the world [ROW]). Treatment continued until disease progression or intolerable toxicity. Primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), overall response rate, and safety. Results Six hundred fifty-six patients (median age, 62.0 years; 73.6% male) were enrolled. Median OS was 5.4 months with everolimus and 4.3 months with placebo (hazard ratio, 0.90; 95% CI, 0.75 to 1.08; P = .124). Median PFS was 1.7 months and 1.4 months in the everolimus and placebo arms, respectively (hazard ratio, 0.66; 95% CI, 0.56 to 0.78). Common grade 3/4 adverse events included anemia, decreased appetite, and fatigue. The safety profile was similar in patients enrolled in Asia versus ROW. Conclusion Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy. The safety profile observed for everolimus was consistent with that observed for everolimus in other cancers. (C) 2013 by American Society of Clinical Oncology | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC CLINICAL ONCOLOGY | - |
dc.subject | MAMMALIAN TARGET | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | RAPAMYCIN | - |
dc.subject | MULTICENTER | - |
dc.subject | GUIDELINES | - |
dc.subject | TRIAL | - |
dc.title | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1200/JCO.2012.48.3552 | - |
dc.identifier.scopusid | 2-s2.0-84891371392 | - |
dc.identifier.wosid | 000330540700016 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.31, no.31, pp.3935 - + | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 31 | - |
dc.citation.startPage | 3935 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | MAMMALIAN TARGET | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RAPAMYCIN | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | TRIAL | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.